Esophageal adenocarcinoma
Therapeutic area
Oncology
Rare disease
Yes
- Definition
- A malignant tumor with glandular differentiation arising predominantly from Barrett mucosa in the lower third of the esophagus. Rare examples of esophageal adenocarcinoma deriving from ectopic gastric mucosa in the upper esophagus have also been reported. Grossly, esophageal adenocarcinomas are similar to esophageal squamous cell carcinomas. Microscopically, adenocarcinomas arising in the setting of Barrett esophagus are typically papillary and/or tubular. The prognosis is poor.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Esophageal adenocarcinoma
- Therapeutic area
- Oncology
- esophageal adenocarcinoma
- adenocarcinoma - esophagus
- adenocarcinoma - oesophagus
- adenocarcinoma of esophagus
- adenocarcinoma of oesophagus
- adenocarcinoma of the esophagus
- adenocarcinoma of the oesophagus
- esophageal adenocarcinoma
- esophagus adenocarcinoma
- oesophageal adenocarcinoma
- oesophagus adenocarcinoma
- Severity
- Severe
- Gastroenterology
- Oncology
- MONDO ID
- MONDO:0005028
- Parent condition
- MONDO:0004970
Related records
Broader conditions (21)
- Adenocarcinoma
- Cancer
- Cancer or benign tumor
- Carcinoma
- Carcinoma of esophagus
- Digestive system cancer
- Digestive system carcinoma
- Digestive system disorder
- Digestive system neoplasm
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Epithelial neoplasm
- Esophageal cancer
- Esophageal disorder
- Glandular cell neoplasm
- Human disease
- Neoplasm
- Neoplasm of esophagus
- Neoplastic disease or syndrome
Narrower conditions (3)
- Barrett adenocarcinoma
- Esophageal adenoid cystic carcinoma
- Mucoepidermoid esophageal carcinoma
Trials (354)
- (VELA) Study of BLU-222 in Advanced Solid Tumors
- 3-AP Plus Cisplatin in Treating Patients With Recurrent or Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction
- A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
- A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
- A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
- A In-Vivo Esophageal Protocol for Detection of Neoplasia in the Digestive Tract
- A Liquid Biopsy for High-risk Pre-cancer Screening of Esophageal Adenocarcinoma
- A Minimally-Invasive Sponge on a String Device for Screening for Barrett's Esophagus
- A Multi-center, Single-arm, Open, Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of EBViNT Cell (EBV Specific Autologous CD8+ T Cell) in Patients With Treatment Failed Epstein Barr Virus (EBV)-Positive Malignancies
- A Multicenter Prospective Cohort Study Comparing Random Biopsies Versus Wide-Area Transepithelial Brush-Sampling (WATS) for Surveillance of Barrett's Esophagus, the WATS-EURO2 Study
- A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
- A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors.
- A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer
- A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma
- A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer
- A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies
- A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer
- A Study of Barrett's Esophagus Patients to Investigate Quality of Life and Fear of Cancer, and Optimize a Risk Model Based on Biomarkers and New Technologies to Better Predict the Development of Cancer
- A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Drugs in development (3)
- Capecitabine Phase 2
- Cisplatin Phase 2
- Epirubicin Phase 2